הבדלים בין גרסאות בדף "טירופיבן - Tirofiban"

טירופיבן - Tirofiban
טירופיבן
התוויות	Aggrastat in combination with heparin, is indicated for patients with unstable angina or non-Q-wave myocardial infarction to prevent cardiac ischemic events and is also indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. In this setting, AGGRASTAT has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction or refractory ischemia/repeat cardiac procedure.

גרסה מ־12:50, 12 במרץ 2014

@@ שורה 9: / שורה 9: @@
 |סל הבריאות=כלול
 |הגבלות=תרופה מוגבלת לרישום ע"י רופא מומחה או הגבלה אחרת.
-|התוויות=Aggrastat in combination with heparin, is indicated for patients with unstable angina or non-Q-wave myocardial infarction to prevent cardiac ischemic events and is also indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. In this setting, AGGRASTAT has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction or refractory ischemia/repeat cardiac procedure.
+|התוויות=Aggrastat in combination with [[heparin]], is indicated for patients with unstable angina or non-Q-wave myocardial infarction to prevent cardiac ischemic events and is also indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. In this setting, AGGRASTAT has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction or refractory ischemia/repeat cardiac procedure.
 |שם יצרן=BAXTER HEALTHCARE CORPORATION, USA
 |שם בעל הרישום=TZAMAL BIO-PHARMA LTD

טירופיבן - Tirofiban
שמות מסחריים	®AGGRASTAT

טירופיבן
קבוצה פרמקולוגית (ATC)	"PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN"
סל הבריאות	כלול
התוויות	Aggrastat in combination with heparin, is indicated for patients with unstable angina or non-Q-wave myocardial infarction to prevent cardiac ischemic events and is also indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. In this setting, AGGRASTAT has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction or refractory ischemia/repeat cardiac procedure.
שם יצרן	BAXTER HEALTHCARE CORPORATION, USA
שם בעל הרישום	TZAMAL BIO-PHARMA LTD
עלון לרופא	"עלון לרופא באנגלית"
יוצר הערך	מערכת ויקירפואה